SC
HALO icon

SummitTX Capital’s Halozyme HALO Stock Holding History

SummitTX Capital’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,550
Closed -$876K – 876
2026
Q1 		$876K Buy
+13,550
New +$955K 0.03% 471
2025
Q4 		– Sell
-4,600
Closed -$337K – 810
2025
Q3 		$337K Buy
4,600
+23
+0.5% +$1.53K 0.01% 606
2025
Q2 		$238K Buy
4,577
+146
+3% +$8.31K 0.01% 660
2025
Q1 		$283K Buy
+4,431
New +$257K 0.01% 670

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

SummitTX Capital's HALO Position: Q2 2026 in Review

SummitTX Capital sold out of Halozyme (HALO) in Q2 2026, closing a stake of 13,550 shares — an estimated $876K sold.

SummitTX Capital first reported a position in HALO in Q1 2025 and held it in 4 quarters. The position peaked at $876K in Q1 2026. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • SummitTX Capital reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • SummitTX Capital sold 13,550 Halozyme shares in Q2 2026, an estimated $876K.
  • SummitTX Capital first reported a position in Halozyme in Q1 2025 and held it in 4 quarters.
  • SummitTX Capital's Halozyme position peaked at $876K in Q1 2026.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.